Pravastatin
Synonym(s)
DefinitionThis section has been translated automatically.
Substance from the group of statins.
Pharmacodynamics (Effect)This section has been translated automatically.
Mode of action: competitive, reversible inhibition of HMG-CoA reductase, the key enzyme determining the rate of cholesterol synthesis; reduction of endogenous cholesterol synthesis and lowering of total cholesterol and LDL cholesterol levels.
PharmacokineticsThis section has been translated automatically.
Naturally produced statin, similar to lovastatin.
Hydrophilic statin, i.e. accumulates on polar cell surfaces and must be taken up into the cell via active transport (therefore, unlike lipophilic statins, it does not act in all cells and presumably has a stronger liver-specific effect than lipophilic statins).
HWZ 1.8 hours.
Low to medium maximum potency with possible LDL reduction dose-dependent: 30 to 40 %
Low metabolization via the liver and predominantly excretion via the kidneys; preferably applicable in chronic liver disease, e.g. also in non-alcoholic or metabolic fatty liver disease (increased cardiovascular risk) (pravastatin, rosuvastatin).
Not applicable in CKD or impaired renal function.
IndicationThis section has been translated automatically.
Hypercholesterolemia.
Primary prevention (cardiovascular risk ≥10% after SCORE2/SCORE2 surgery).
Secondary prevention.
FH from 8 years of age.
Post-transplantation with immunosuppressive therapy.
Pregnancy/nursing periodThis section has been translated automatically.
Cholesterol and other intermediate products of cholesterol biosynthesis are essential in embryonic and fetal development and necessary for the synthesis of steroids and cell membranes!
Statins are therefore contraindicated during pregnancy and breastfeeding.
The potential risk of damage justifies a break in therapy.
Women and young girls of childbearing age need effective contraception (note interactions!).
For further information, see specialist information!
In the event of unexpected pregnancy during treatment, see "Embryotox Charité".
InteractionsThis section has been translated automatically.
Enzyme systems/carriers and selection of substances with potential for interaction (inhibition), enhancement of effect and risk of serious adverse effects with concomitant treatment with pravastatin
OATP1B1
- Carbamazepine, clarithromycin, ciclosporin, erythromycin, gemfibrozil, protease inhibitors (HIV), roxithromycin, sacubitril
Generally low risk for WW, as only low metabolism via the liver or Cyt P 450.
Combination with fibrates not recommended.
For further information and for substances that can be used with dose restrictions, see the technical information.
This information is only a selection! Further interactions must be clarified individually in each case! (for further information, see specialist information or databases on drug interactions).
It should also be noted that statins can alter the effect of concomitant medication and this can also result in additional incompatibilities!
Interaction studies have only been carried out in adults.
Especially in special patient groups with polypharmacotherapy, the risk of side effects is increased!
PreparationsThis section has been translated automatically.
Pravastatin (generics) 10 mg, 20 mg, 40 mg
LiteratureThis section has been translated automatically.
- Expert info Pravastatin: https://www.fachinfo.de/fi/detail/014230/pravastatin-ratiopharm-r-10-mg-20-mg-40-mg-tabletten
- Mach F et al (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) European Heart Journal 41;1:111-188 https://doi.org/10.1093/eurheartj/ehz455
-
Pravasin® protect 10/20/40 mg https://fi.b-ms.de